Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study

Inclusion Criteria

• •A) low restenosis risk based on angiographic findings defined as follows:
• •---patients will be considered at low restenosis risk if no planned stent lower than 3.0 mm is intended to be implanted in lesions expect left main or vein graft
• •B) high bleeding risk and/or presence of relative-absolute contraindication to dual anti-platelet treatment beyond 30 days defined as follows:
• •1. Clinical indication to treatment with oral anticoagulant, including use of warfarin or dabigatran or other oral anticoagulant agents
• •2. Recent (within previous 12 months) bleeding episode(s) which required medical attention
• •3. Previous bleeding episode(s) which required hospitalization if the bleeding diathesis has not been completely resolved (i.e. surgical removal of the bleeding source)
• •4. Age greater than 80
• •5. Systemic conditions associated to increased bleeding risk (e.g. hematological disorders or any known coagulopathy determining bleeding diathesis, including history of or current thrombocytopenia defined as platelet count \<100,000/mm3 (\<100 x 109/L).
• •6. Known Anemia defined as repeatedly documented hemoglobin lower than 10 gr/dl which is not due to an acute and documented blood loss
• •7. Need for chronic treatment with steroids or NSAID
• •C) Patients at high thrombosis risk based on the presence of at least one of the following criteria:
• •1. Allergy/intolerance to aspirin
• •2. Allergy/intolerance to clopidogrel AND ticlopidine
• •3. Planned surgery (other than skin) within 12 months of percutaneous coronary intervention (PCI).
• •4. patient with cancers (other than skin) and life expectancy \>1 year
• •5. Patients with systemic conditions associated with thrombosis diathesis (e.g., hematologic disorders and any known systemic conditions determining a pro-thrombotic state including immunological disorders)
• •\-